This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Kenyon-Smith TJ , Kroon HM , Miura JT , Teras J , Beasley GM , Mullen D , Farrow NE , Mosca PJ , Lowe MC , Farley CR , Potdar A , Daou H , Sun J , Farma JM , Henderson MA , Speakman D , Serpell J , Delman KA , Smithers BM , Barbour A , Coventry BJ , Tyler DS , Zager JS , Thompson JF
Factors predicting toxicity and response following isolated limb infusion for melanoma: An international multi-centre study
Eur J Surg Oncol. 2020 Nov;46(11) :2140-2146
PMID: 32739218 URL: https://www.ncbi.nlm.nih.gov/pubmed/32739218
AbstractINTRODUCTION: Isolated limb infusion (ILI) is a minimally-invasive procedure for delivering high-dose regional chemotherapy to treat melanoma in-transit metastases confined to a limb. The aim of this international multi-centre study was to identify predictive factors for toxicity and response. METHODS: Data of 687 patients who underwent a first ILI for melanoma in-transit metastases confined to the limb between 1992 and 2018 were collected at five Australian and four US tertiary referral centres. RESULTS: After ILI, predictive factors for increased limb toxicity (Wieberdink grade III/IV limb toxicity, n = 192, 27.9%) were: female gender, younger age, procedures performed before 2005, lower limb procedures, higher melphalan dose, longer drug circulation and ischemia times, and increased tissue hypoxia. No patient experienced grade V toxicity (necessitating amputation). A complete response (n = 199, 28.9%) was associated with a lower stage of disease, lower burden of disease (BOD) and thinner Breslow thickness of the primary melanoma. Additionally, an overall response (combined complete and partial response, n = 441, 64.1%) was associated with female gender, Australian centres, procedures performed before 2005, lower limb procedures and lower actinomycin-D doses. On multivariate analysis, higher melphalan dose remained a predictive factor for toxicity, while lower stage of disease and lower BOD remained predictive factors for overall response. CONCLUSION: ILI is safe and effective to treat melanoma in-transit metastases. Predictive factors for toxicity and response identified in this study will allow improved patient selection and optimization of intra-operative parameters to increase response rates, while keeping toxicity low.
Notes1532-2157 Kenyon-Smith, Timothy J Kroon, Hidde M Miura, John T Teras, Jüri Beasley, Georgia M Mullen, Dean Farrow, Norma E Mosca, Paul J Lowe, Michael C Farley, Clara R Potdar, Aishwarya Daou, Hala Sun, James Farma, Jeffrey M Henderson, Michael A Speakman, David Serpell, Jonathan Delman, Keith A Smithers, B Mark Barbour, Andrew Coventry, Brendon J Tyler, Douglas S Zager, Jonathan S Thompson, John F Journal Article England Eur J Surg Oncol. 2020 Jul 13:S0748-7983(20)30565-5. doi: 10.1016/j.ejso.2020.06.040.